Medicine News Car T Cell Therapy Reaches Beyond Cancer Penn Medicine

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ... Read More

Expanding CAR T-Cell Access With Broader Criteria and Real-World Data: Clark Alsfeld, MD

At the Institute for Value-Based Medicine ® event in New Orleans, Louisiana, on November 4, Clark Alsfeld, MD, a hematology and oncology specialist at Ochsner MD Anderson, spoke about the availability ... Read More

Enhanced CAR T cell therapy offers new strategy for lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ... Read More

Next-generation CAR T cells could expand solid cancer treatment options

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ... Read More

Study reveals why some myeloma patients stay cancer-free for years after CAR T therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ... Read More

VIDEO: Differences in CAR-T therapy examined at LLM

In this video, Catherine S. Diefenbach, MD, discusses the differences between three FDA-approved CD19-directed chimeric antigen receptor T-cell therapy products for the treatment of lymphoma. Read More

Reviving Exhausted T Cells Sparks Powerful Cancer Tumor Elimination

Researchers found a hidden signal that makes T cells shut down during cancer fights. Turning off this signal reawakens the cells and helps them attack tumors more effectively. Read More

CAR-T cell therapy for cancer causes 'brain fog,' study shows

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it. After treatment with CAR-T cells ... Read More

Dual-Target CAR-T Cell Therapy Slows Glioblastoma Tumors in Phase I Trial

Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months ... Read More

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ... Read More

CAR-T cell therapy for cancer causes 'brain fog,' study shows

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating. A ... Read More